CLINICAL_TRIALS
trial_result
· 2025-06-12
Clinical Trial Update: A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder [Phase 2]
Summary
Phase 2 study evaluating SP-624 for adults with Major Depressive Disorder has completed, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sirtsei Pharmaceuticals, Inc. | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2025-06-12